Lazertinib Clinical Trials
7 recruitingDrug
Phase 27
Showing 1–7 of 7 trials
Recruiting
Phase 2
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Janssen Research & Development, LLC480 enrolled196 locationsNCT06667076
Recruiting
Phase 2
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
Janssen Research & Development, LLC300 enrolled93 locationsNCT06120140
Recruiting
Phase 2
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Janssen Research & Development, LLC520 enrolled110 locationsNCT05498428
Recruiting
Phase 2
Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment
Samsung Medical Center47 enrolled1 locationNCT06106802
Recruiting
Phase 2
Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Yonsei University160 enrolled1 locationNCT06268210
Recruiting
Phase 2
To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation
Advanced Solid Tumors
Abion Inc178 enrolled24 locationsNCT05541822
Recruiting
Phase 2
A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker
Lazertinib
National Cancer Center, Korea120 enrolled5 locationsNCT06156527